Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05833217 · ClinicalTrials.gov registry record · NA
Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2
A NA study of Insulin Resistance and Long COVID, sponsored by Stanford University.
- Recruiting
- Registry status
- NA
- Development phase
- 55
- Enrollment target
- 2
- Study locations
NCT05833217 is a NA study of Insulin Resistance and Long COVID that is actively recruiting participants, run by Stanford University. The registered enrollment target is 55 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05833217, a NA study of Insulin Resistance and Long COVID, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
- 2
- Study locations
Study Summary
The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir for SARS-CoV-2 persistence. The results will not only determine whether obesity and IR are risk factors for PASC, but will also define fundamental biology that sets the stage for the investigation of novel or existing therapies that target the causal pathways identified.
Conditions Studied
Interventions
- PROCEDURE Adipose Tissue Biopsy
- DIAGNOSTIC_TEST Steady State Plasma Glucose (SSPG) Test
Study Locations (2)
California
- Clinical and Translational Research Unit - Palo Alto
- Stanford Health - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2023-06-06 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05833217
The ClinicalTrials.gov registry entry for NCT05833217 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (78% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Insulin Resistance appearing as the primary indexed condition, and to 2 interventions - of which Adipose Tissue Biopsy is the first listed.
NCT05833217 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05833217 about?
NCT05833217 is a clinical study titled "Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2". The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir ...
What is the current status of trial NCT05833217?
This trial is currently recruiting. It is a NA study. The enrollment target is 55 participants. The study started on 2023-06-06. Estimated completion is 2025-12-31.
What conditions does trial NCT05833217 study?
This clinical trial studies the following conditions: Insulin Resistance, Long COVID, Insulin Sensitivity.
What interventions are being tested in trial NCT05833217?
The interventions under investigation include: Adipose Tissue Biopsy (PROCEDURE), Steady State Plasma Glucose (SSPG) Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05833217?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05833217 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Resistance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
RECRUITING · NA
-
Small Extracellular Vesicles and Insulin Action
RECRUITING · NA
-
Exercise Effects on Adipose Tissue Structure and Function
RECRUITING · NA
-
New Mechanisms of Obesity
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.